GlyT1 - Up from the Ashes. The importance of not condemning a mechanism based on a single chemotype.
作者信息
Lindsley Craig
出版信息
ACS Chem Neurosci. 2010 Mar 17;1(3):165-6. doi: 10.1021/cn100017a.
Abstract
摘要
相似文献
1
GlyT1 - Up from the Ashes. The importance of not condemning a mechanism based on a single chemotype.
ACS Chem Neurosci. 2010 Mar 17;1(3):165-6. doi: 10.1021/cn100017a.
2
Inhibitors of GlyT1 affect glycine transport via discrete binding sites.
Mol Pharmacol. 2008 Dec;74(6):1705-15. doi: 10.1124/mol.108.049312. Epub 2008 Sep 24.
3
Transmembrane domains 1 and 3 of the glycine transporter GLYT1 contain structural determinants of N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)-propyl]sarcosine specificity.
Neuropharmacology. 2005 Nov;49(6):922-34. doi: 10.1016/j.neuropharm.2005.07.010. Epub 2005 Sep 6.
4
Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice.
Biochem Pharmacol. 2010 Nov 1;80(9):1407-17. doi: 10.1016/j.bcp.2010.07.004. Epub 2010 Jul 15.
5
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
Neuropharmacology. 2008 Oct;55(5):743-54. doi: 10.1016/j.neuropharm.2008.06.016. Epub 2008 Jun 17.
6
Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
Curr Opin Mol Ther. 2008 Dec;10(6):591-601.
7
In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors.
Ann N Y Acad Sci. 2003 Nov;1003:412-4. doi: 10.1196/annals.1300.039.
8
The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.
J Neurosci. 2003 Aug 20;23(20):7586-91. doi: 10.1523/JNEUROSCI.23-20-07586.2003.
9
Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors.
Curr Top Med Chem. 2010;10(2):170-86. doi: 10.2174/156802610790410974.
10
Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential.
Pharmacol Biochem Behav. 2010 Dec;97(2):185-91. doi: 10.1016/j.pbb.2010.07.016. Epub 2010 Aug 1.
引用本文的文献
1
Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain.
Br J Pharmacol. 2013 Nov;170(5):1053-63. doi: 10.1111/bph.12343.
2
Prepulse inhibition of the startle reflex and response to antipsychotic treatments in two outbred mouse strains in comparison to the inbred DBA/2 mouse.
Psychopharmacology (Berl). 2011 Jun;215(3):441-54. doi: 10.1007/s00213-011-2196-5. Epub 2011 Feb 8.
本文引用的文献
1
Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
Curr Opin Mol Ther. 2008 Dec;10(6):591-601.
2
Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors.
Curr Top Med Chem. 2006;6(17):1883-96. doi: 10.2174/156802606778249784.
3
Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
Curr Top Med Chem. 2006;6(8):771-85. doi: 10.2174/156802606777057599.
4
N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review.
Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):191-213. doi: 10.2174/1568007024606258.
5
NMDA receptor hypofunction model of schizophrenia.
J Psychiatr Res. 1999 Nov-Dec;33(6):523-33. doi: 10.1016/s0022-3956(99)00029-1.
6
Recent advances in the phencyclidine model of schizophrenia.
Am J Psychiatry. 1991 Oct;148(10):1301-8. doi: 10.1176/ajp.148.10.1301.
Zotero 插件